Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GeriaSan
Zug, Zug, Switzerlandgeriasan.ch ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
GeriaSan is a Swiss-based biotechnology company focused on developing and commercializing evidence-based solutions for healthy aging and geriatric care. The company specializes in the research of metabolic pathways associated with longevity, specifically targeting mechanisms like sirtuin activation and mTOR inhibition to address age-related conditions such as sarcopenia and cognitive decline. GeriaSan bridges the gap between pharmaceutical research and high-end nutraceuticals, offering products designed to maintain physical and mental vitality in the elderly. Their business model encompasses both the development of proprietary formulations and the provision of specialized health services for the geriatric population.
- Therapeutic areas
- NeurologyOtherMetabolic Disorders
- Modalities
- Small moleculeNutraceutical
- Industry
- Biotech
Beyond the preview
Go deeper on GeriaSan.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeriaSan.